A Phase 2/3 Study of Osivelotor in Sickle Cell Disease

Recruiting Phase 2,Phase 3 NCT05431088

Study Description

A Study to Evaluate the Safety and Effectiveness of a New Drug Called Osivelotor in People with Sickle Cell Disease

Study Details

Registry ID:
NCT05431088
Conditions:
Sickle Cell Disease
Phase:
Phase 2,Phase 3
Target Enrollment:
389 participants
Start Date:
Age Range:
12–999 years
Healthy Volunteers:
No

Study Locations (68 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →